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Abstract
Osteoarthritis is complex in genetics, pathogenesis, monitoring and treatment. Current
treatment of osteoarthritis does not influence progression. Much could be gained by more
effective ‘low-tech-low-cost’ treatment. However, many patients have rapidly progressive
disease, multiple joint involvement, and severe disease. We need to clarify the genetics of
osteoarthritis, identify those at risk for progression and severe disease, and identify
molecular processes critical for joint survival and failure. Will saving the cartilage improve
patient pain and function? Effective outcome measures are needed to accelerate testing of
new treatments. Further improvement is needed in joint implant technology to decrease
costs, wear and loosening.
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Introduction
Joint diseases affect hundreds of millions of patients
throughout the world, causing pain and disability with
great impact on individuals and on society as a whole.
Osteoarthritis is the most common joint disease; in the
near future, it is projected to rank second for women and
fourth for men in the developed countries in terms of years
lived with disability [1]. Elderly patients are most often
affected (joint diseases account for half of all chronic con-
ditions in persons aged 65 years and over) and, because
the number of individuals over the age of 50 years is
expected to double worldwide between 1990 and 2020,
the global burden of osteoarthritis will increase dramati-
cally. In Europe by 2010 there will be more people aged
over 60 years than under 20 years, and by 2020 these
elderly individuals will represent 25% of the population.
Unless we invest in increased research and education
now to decrease the future burden of joint disease,
osteoarthritis in the ageing population will generate a
global avalanche of costs and disability [2].
Risk factors
Osteoarthritis is a complex disorder and has high popula-
tion prevalence. It is genetically complex, because it gen-
erally lacks a clear Mendelian pattern of inheritance and is
probably associated with interactions of multiple genes.
The fact that disease initiation, progression and severity
may be influenced by multiple environmental factors inter-
acting with multiple variations in the genetic background
adds further complexity. Furthermore, the distinction
between disease and nondisease is often problematic.
Genetic factors are thus recognized as being associated
with osteoarthritis, and epidemiological studies [3–10] have
illustrated the influence of heredity on common forms of
osteoarthritis. Further examples of a genetic predisposition
for osteoarthritis are given by rare subtypes of osteoarthritis
that appear to have a basis in single gene mutations and are
associated with early age onset (for review [11]). Examples
of mutated genes that may be responsible for these dis-
eases include those that encode cartilage-specific colla-Arthritis Research    Vol 2 No 2 Lohmander
gens and cartilage oligomeric matrix proteins [12–19].
Additional reports [20–23] have presented evidence for
and against the association of osteoarthritis with yet other
genes that may encode molecules that are related to carti-
lage function. The availability of DNA collections from large
numbers of families and sibling pairs with osteoarthritis,
coupled with novel techniques for genome-wide scans, are
now identifying evidence for yet other predisposing multiple
chromosomal loci for osteoarthritis [24–26].
Environmental factors interact with this variable genetic
background. For example, joint malalignment, overloading
(eg related to work or high body weight) and injury are rec-
ognized risk factors that predispose to osteoarthritis to
varying degrees [27]. The impacts of such risk factors in
different joints vary. For example, obesity in women is
associated with an increased risk for knee osteoarthritis,
but the effect in males and in the hip is less well estab-
lished [4,28–30]. Acute injuries to the ligaments and
menisci of the knee are well-recognized and common
causes of osteoarthritis [31]. For example, meniscus injury
followed by surgical removal is associated with a relative
risk of 14 for radiological osteoarthritis, over that of age-
matched and sex-matched control individuals [32]. In com-
parison, relative risks associated with obesity, work and
other factors are more modest and usually range between
2 and 4 [27]. From a research perspective, injury-related
development of osteoarthritis has the distinct advantage
that the human osteoarthritis disease process can be fol-
lowed from its earliest stages.
Progression of disease
Disease progression in osteoarthritis is usually slow, and
occurs over years or decades. The rate of progression is
variable between individuals, and many patients with clini-
cally diagnosed osteoarthritis may not suffer appreciable
progression by either symptoms or radiographic changes
over long periods [33–36]. Progression may also be vari-
able over time in the same individual, and joint destruction
may occur in episodes.
The distinction between disease and nondisease is prob-
lematic in osteoarthritis, and complicates most aspects of
osteoarthritis research, including epidemiology and genet-
ics research. The ‘clinical’ definition of osteoarthritis for
use in, for example, clinical trials is usually based on a
defined combination of symptoms and plain radiography
changes that are caused by altered joint structure. The
correlation between the degree of radiological change and
symptoms is weak, however, and it is common for patients
with radiological osteoarthritis to have few or no symp-
toms, whereas classical symptoms of osteoarthritis may
occur in the absence of structural changes on plain radio-
graphy [37]. The current definition of osteoarthritis needs
to be operational and adapted to the purpose and tools of
specific areas of research.
Pathophysiology
The osteoarthritis disease process at the tissue and cellu-
lar level is associated with destruction and loss of carti-
lage, remodelling of bone and intermittent inflammation.
Although research focus remains on the destruction of
joint cartilage, changes in subchondral bone, synovium
and ligaments are detectable at an early stage in
osteoarthritis. The roles played by events that take place in
these tissues in the initiation and progression of
osteoarthritis remain to be clarified. The complexity of the
osteoarthritis process is further underlined by the increase
in synthesis of cartilage matrix components that can be
detected concurrently with increased degradation of carti-
lage matrix [38,39].
Degradation and synthesis of cartilage matrix in
osteoarthritis are driven by mediators that are released by
chondrocytes and synoviocytes. These mediators include
cytokines (such as interleukin-1 and tumour necrosis
factor), nitric oxide and growth factors [40–42]. Events
that in turn may drive the increased release of these medi-
ators include changes in chondrocyte loading that are
induced by joint overload or injury [43]. These events act
within a tissue environment where cartilage matrix quality
and cellular reactivity may in part be determined by
genetic variation. Thus, a minor insult may initiate
osteoarthritis in a less resistant environment, whereas in
another individual the joint may be able to compensate for
a greater insult. Treatments aimed at preserving or regen-
erating functional tissue may be ineffective because they
may be overwhelmed by mechanical processes.
Evidence suggests that synovial-derived and/or cartilage-
derived proteases play a critical role in cartilage matrix
degradation, with matrix metalloproteases and aggre-
canases currently attracting the most attention [44–47].
Together, these proteases have the ability to degrade the
major macromolecular constituents of the cartilage matrix,
such as collagens, aggrecan and matrix proteins. Ulti-
mately, elevated matrix degradation results in complete
loss of the cartilage and loss in joint function. As men-
tioned above, the cartilage may in some situations be able
to compensate for matrix loss induced by an insult. The
‘point of no return’ beyond which compensation is impos-
sible has not been identified, but may include proteolytic
damage to some part of the collagen network, or loss of
critical interactions between matrix components.
Measuring osteoarthritis
Outcome measures in osteoarthritis research include
patient-relevant measures, structural measures and
process biomarkers in the form of molecules or molecular
fragments that are released as a result of joint tissue
metabolism [48–52]. Effective outcome measures are criti-
cal to many aspects of osteoarthritis research, and in par-
ticular to clinical trials of new treatments. There is nohttp://arthritis-research.com/content/2/2/095
current ‘gold standard’ for the diagnosis of osteoarthritis.
Although ongoing clinical drug trials with osteoarthritis
disease modification as the goal mostly use standardized
plain radiographs to monitor structural changes in the joint,
the good relationship between preservation or improve-
ment of joint structure (eg joint space) and improvement in
patient-relevant symptoms and function remains an hypoth-
esis that is still to be proven. Magnetic resonance imaging
is rapidly evolving as a method to monitor joint structure,
and with time may become the preferred method to
monitor this feature in osteoarthritis research and clinical
trials. Similarly, osteoarthritis biomarker research is receiv-
ing increased attention as a promising modality to monitor
changes in joint tissue turnover, predict osteoarthritis pro-
gression, select patients for clinical trials, and monitor
response to treatment with drugs designed to prevent
certain disease features, such as cartilage degradation.
Current treatments
The patient with osteoarthritis suffers from pain and loss of
function. From the patient’s perspective, alleviation of such
features of disease is what counts, so what can we do
about osteoarthritis at present?
Our current modes of treatment to decrease pain and
improve functioning range from information, education,
physical therapy and aids, through analgesics, non-
steroidal anti-inflammatory drugs and joint injections, and
to surgery in which all or part of the joint is replaced with
plastic, metal or ceramic implants. The informed patient is
a further critical aspect in all management approaches to
chronic diseases such as osteoarthritis. The currently
available treatment modalities listed above can decrease
pain and improve functioning, with joint replacement in
late-stage osteoarthritis perhaps being the most effective
in this regard. Evidence-based reviews of current
osteoarthritis treatment [53] emphasize the moderate
effectiveness of many of the current treatments for
osteoarthritis, however. There is no generally accepted
and available means of influencing the progression of the
disease, and thus all current treatment for osteoarthritis is
palliative. The frequent dissociation between change in
joint structure and occurrence of symptoms suggests that
many first-time patients who seek medical care for joint
pain will already have advanced destruction of their joint
cartilage. This has implications for our ambitions to pre-
serve cartilage by pharmacological or other interventions.
Future treatments
The above brief overview emphasizes that osteoarthritis is
important from the perspective of the patient and society
as a whole, and is projected to become one of the condi-
tions with the highest impact; that current treatments often
lack effectiveness; and that our understanding of the
causes and disease mechanisms that are involved in
osteoarthritis is incomplete.
What will we be able to do about osteoarthritis in the
future? Although this commentary focuses on research
that utilizes sometimes sophisticated technologies and
treatments, we need to remind ourselves that much of this
might not be very relevant to all of the elderly, common,
‘garden-variety’ patients (including those in the developing
countries) with mild or moderately symptomatic
osteoarthritis. Consequently, future research also needs to
be directed to the development and evaluation of effective
‘low technology/low cost’ methods for dealing with the
problems of these patients in a rational way [54]. The
launch of the ‘Bone and Joint Decade 2000–2010’ is a
timely event that will provide further support for research
and education to decrease the growing global burden and
cost of musculoskeletal diseases [2] (http://www.bone-
jointdecade.org).
What can arthritis research do about osteoarthritis for
patients who are young, for those with rapidly progressive
disease, for those with multiple joint involvement, and for
those with severe disease? A few suggestions may be
offered, looking at some of the current research questions
and emerging new technologies. The genetics and epi-
demiology of different forms of osteoarthritis will need to
be further clarified. A better understanding of the impact
of environmental risk factors and their interaction with
genetic background may result in possibilities for disease
prevention. We need to be able to identify those patients
who are at risk for progression and severe disease earlier,
and we need to focus more of our attention on these
patients. Molecular processes that are critical for cartilage
and joint failure need to be identified. For cartilage protec-
tion, the matrix and cell features that are critical for survival
of the tissue must be better understood, and crucial
degradative agents, such as proteases, identified. What is
the role of failed matrix synthesis and regeneration as a
cause of joint failure? Will saving the cartilage improve
pain and functioning? The role of local inflammation in
osteoarthritis, not detected by the usual clinical signs, but
by the role of cytokines, will need increased attention.
More effective outcome measures are needed to acceler-
ate testing of new treatments. Many patients with severe
osteoarthritis will continue to need joint replacements; we
need to improve on existing implant technology in order to
decrease costs, enhance osseointegration and minimize
wear, osteolysis and loosening.
Osteoarthritis is a highly prevalent, genetically complex
disorder. Several large-scale investigations involving thou-
sands of patients and genome-wide screening are now
underway that are likely to identify multiple gene variations
associated with an increased risk for osteoarthritis within a
fairly short period. Any such variation identified in a spe-
cific population will then need to be confirmed in other
populations to ascertain generalizability. The identification
of specific and common genetic variations associated withincreased osteoarthritis risk will improve our understand-
ing of the disease processes involved in osteoarthritis, and
may in addition provide targets for development of new
forms of treatment. It may in this context be interesting to
compare the model for inheritance of osteoarthritis with
that for Alzheimer’s disease, in which a genetic dichotomy
model is proposed [55]. In this model rare forms of inher-
ited diseases are caused by rare, highly penetrant muta-
tions with severe impact and early onset, whereas more
common forms of the same disease that occur with
increased frequency and at older age are associated with
genetic risk factors in the form of common population
polymorphisms. The imminent mapping of the human
genome will greatly accelerate such investigations.
Further developments in molecular biology such as
microarray chips allow simultaneous large-scale differen-
tial identification of thousands of genes expressed (tran-
scriptomes) in disease [56]. This will further enhance our
ability to identify molecules and processes that are rele-
vant to osteoarthritis pathology [42], and will certainly
identify additional targets for pharmacological treatment.
The large number of candidate molecules and processes
thus identified for testing will challenge bioinformatics
research.
Industry drug discovery and development are also being
revolutionized by technological advances. The application
of high throughput screening, high throughput compound
synthesis and rational drug design will be needed to take
advantage of the exponential increase in number of poten-
tial targets. At the trial and user end pharmacogenomics
aided by microarray technology, promises to provide indi-
vidualized information that will aid in selection of trial
patients and optimal forms of treatment for the individual.
The cost-effective monitoring of clinical trial outcomes still
presents a challenge, and it has been proposed that bio-
markers in osteoarthritis is an area that is now suitable for
large-scale collaborative projects between industry, acad-
emic institutions and federal agencies (Osteoarthritis Ini-
tiative, http://www.nih.gov/niams/news/oisg/index.htm). It
is proposed that such a collaboration could identify and
evaluate biomarkers as surrogate end-points for clinical
trials in osteoarthritis. If validated as surrogate end-points,
use of such markers would accelerate the evaluation of
new drugs in clinical trials and decrease the needed
number of patients. As noted above, the potential future
increase in number of drug candidates to be evaluated
provides ample reason for increased efforts in this area.
The continued identification of biomarkers of osteoarthritis
in the form of molecules or molecular fragments that
reflect events in the diseased joint will no doubt be further
accelerated by the new technologies to identify genes that
are differentially expressed in disease. Such methods, in
concert with proteomics and a fully mapped human
genome, will likely provide a rich selection of biomarkers to
test in human disease. This will, in turn, require access to
large, well-characterized cohorts of patients (and control
individuals) who are identified and managed by clinical
investigators. Perhaps the availability of these human
resources will remain the most significant bottleneck in our
continued efforts to provide better treatment for
osteoarthritis patients through research.
Conclusion
The genetics, pathogenesis, monitoring and treatment of
osteoarthritis are complex. Evidence-based reviews point
to the moderate effectiveness of current osteoarthritis
treatments. There is no accepted means of influencing
progression of human osteoarthritis. Although much can
be gained by effective ‘low technology/low cost’ methods
for dealing with osteoarthritis in many patients, such
approaches are not appropriate for the many patients with
rapidly progressive disease, multiple joint involvement and
severe disease. For such patients, the genetics and epi-
demiology of osteoarthritis need to be further clarified. A
better understanding of environmental risk factors and
their interaction with genetic background may improve
preventive efforts. We need to identify those who are at
risk for progression and severe disease. Molecular
processes that are critical for joint failure also need to be
identified. For cartilage protection, the matrix and cell fea-
tures that are critical for survival of the tissue must be
understood and crucial degradative agents identified.
What is the role of failed matrix synthesis and regenera-
tion? Will saving the cartilage improve patient pain and
functioning? The role of local inflammation in osteoarthritis
needs increased attention. More effective outcome mea-
sures are needed to accelerate testing of new treatments.
Many patients with severe osteoarthritis will continue to
need joint replacements, and we need to improve on exist-
ing implant technology in order to decrease costs, wear
and loosening. 
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